Clinical Trial Update: Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients [Phase 2]

View source ↗

Summary

A Phase 2 safety pilot study of a Farnesoid X Receptor (FXR) agonist in non-alcoholic fatty liver disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• FXR agonist (farnesoid X receptor agonist)

Snippet

Sponsor: Phenex Pharmaceuticals AG | Conditions: Non Alcoholic Fatty Liver Disease | Phase 2 | Status: COMPLETED